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Repeated ultrasound-guided intra-articular injections of 40mg of
Hyalgan may be useful in symptomatic relief of hip osteoarthritis
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SocietySir,
Symptomatic osteoarthritis (OA) patient management in-
cludes the use of non-pharmacological therapies, analge-
sics, physiotherapy and eventually surgery. Whereas local
injections (e.g., corticosteroids, hyaluronan) are easily per-
formed on the knee, hip injections are considerably more
difﬁcult1. Recent literature proves that ultrasound (US)-guided
hip injections are safe and allow easy access to the hip joint
space2,3. Steroids may be injected in this space, but the
symptomatic beneﬁt achieved by intra-articular administra-
tions of hyaluronans appears to last longer.
This open-label pilot study was aimed at investigating the
safety and duration of beneﬁt after the treatment of hip OA
patients by US-guided intra-articular injections of 40 mg of
Hyalgan, equivalent to two 2-ml tubes. Hyalgan is a natu-
ral hyaluronan with a molecular weight of 500e730 kDa that
is able to reduce pain associated with OA and to ameliorate
joint function. Recent clinical data have shown intra-articu-
lar hyaluronans to exert also a positive effect in reducing
the progression of the joint disease4.
Materials and methods
Adult outpatients with hip OA deﬁned according to
American College of Rheumatology criteria5 were enrolled
(Table I), and their hips X-rayed and graded 1e4 according
to the KellgreneLawrence score. Exclusion criteria were
concomitant anticoagulant and/or steroid therapy. Two
syringes of Hyalgan 20 mg, equivalent to 40 mg (4ml),
were injected under US guidance in symptomatic hips. A
second injection was repeated in all patients 30 days after
the ﬁrst one. Patients were seen again at 3-month intervals.
Patients were examined supine, by the anterior parasa-
gittal approach. A 3.5 MHz convex transducer, with a steril-
ized biopsy guide attached was aligned with the long axis of
the femoral neck, including also the acetabulum and the
femoral head. Intra-articular hyaluronan placement was en-
sured by real-time US visualization and Doppler signal of
viscous ﬂuid or air bubbles entering the intra-articular re-
cess. Colour Doppler vision makes it possible to avoid in-
jecting blood vessels. According to Outcome Measures in
Rheumatology Clinical Trials indications, treatment efﬁcacy
was assessed by Lequesne index, monthly non-steroidal
anti-inﬂammatory drug (NSAID) intake, visual analogue
scale (VAS) pain measurement, global patient assessment
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E-mail: alberto.migliore@tin.it112and global physician assessment; all these scores were re-
corded at baseline and, then, at visits 3, 6, 9 and 12 months
after enrolment. All adverse events were reported.
When, at the visits, both physician and patient judged the
outcome of the injections to be unsatisfactory on the basis
of changes in the parameters considered, the patients were
allowed to undergo repeated injections.
Results
Fourteen patients (three males, 11 females, mean age
71.64G 10.92 years) were enrolled, ﬁve of whom had bilat-
eral hip OA (Table I). Altogether, 19 hips were treated. The
KellgreneLawrence radiological grade was 2 in six hips, 3
in nine hips and 4 in four hips. Six patients received only
two injections, seven received a third injection 3e7 months
after the second, and one patient also received a fourth in-
jection 5 months after the third. A total of 48 injections were
performed. All patients were followed up for 12 months, ex-
cept two, who dropped out at 9 months because of depres-
sive mood affection and personal reasons, respectively. No
infectious or systemic complications were reported.
Paired t test and non-parametric Wilcoxon signed ranks
test were performed for each of the outcomes, comparing
values collected at baseline (time 0) with the 3-, 6-, 9-,
12-month timepoints (Table II).
Table I
Demographic characteristics of the patients on an intention-to-treat
basis (Pt, patient)
Patients (n) 14
Males 3
Females 11
Age, years (GSD) 71.64 (G10.92)
Smoking habit 1 pt
Systemic OA 12 pts
Knee OA 7 pts
Hip treatment
Monolateral 9 pts
Bilateral 5 pts
Comorbidities
Hypertension 7 pts
Diabetes 2 pts
Number of injections*
Two 6 pts
Three 7 pts
Four 1 pt
*Subsequent injections were administered at an interval of 3e6
months.6
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Results and the mean values registered at the different timepointsG SD (see text)
Baseline 3 months 6 months 9 months 12 months
Pain VAS 6.5G 2.1** 4.4G 2.1** 5.0G 2.3** 4.3G 3.2** 3.5G 3.0**
Lequesne 11.3G 5.7** 5.9G 4.4** 6.9G 5.3** 8.0G 7.5** 6.9G 6.1**
NSAID cons. 6.9G 8.6** 2.6G 5.7** 2.0G 5.2** 3.9G 8.3* 3.1G 8.5**
Ph Gl Ass 5.7G 1.6** 3.6G 1.7** 3.9G 1.6** 3.4G 2.2** 3.3G 2.4**
Pt Gl Ass 6.0G 2.0** 4.0G 1.7** 4.5G 1.9** 4.4G 2.9** 3.5G 2.6**
Pain VAS: pain visual analogue scale (0e10); Lequesne: Lequesne index (0e10); NSAID cons.: NSAID consumption expressed in days of
intake per month (0e30); Ph Gl Ass: physician global assessment (0e10); Pt Gl Ass: patients global assessment (0e10).** P values! 0.05.
*Paired t test: PZ 0.37; Wilcoxon: PZ 0.16.The results, computed with and without the drop-out,
show that there are signiﬁcant changes at the VAS and Le-
quesne index at all timepoints compared to baseline (all P
values! 0.05); the decrease in pain VAS and Lequesne in-
dex at 12 months was 43% and 36%, respectively, com-
pared to baseline.
As for NSAIDs, different results were obtained with and
without the drop-out: in the ﬁrst case, paired t test and
non-parametric Wilcoxon signed ranks test were signiﬁcant
at all timepoints except 9 months, compared to baseline
( paired t test: PZ 0.37; Wilcoxon: PZ 0.16); without the
drop-out, both tests proved signiﬁcant at all timepoints (all
P values! 0.05).
For global patient evaluation and global physician evalu-
ation, all tests reached signiﬁcance (computed with and
without the drop-out), indicating improvements at all time-
points compared to baseline (all P values! 0.05); global
patient evaluation and global physician evaluation had de-
creased at 12 months by 38% and 41%, respectively, when
compared to baseline.
Stratifying data according to the KellgreneLawrence
score, the most satisfying outcomes are achieved when
treating initial and intermediate OA scores. Grade 4 patients
get poor and short-lived beneﬁt from the injection, both for
pain evaluation and functional status.
Discussion
In this open-label study we propose the administration of
Hyalgan at the regimen of 40 mg (corresponding to 4 ml)
at least at baseline and after 1 month, to be repeated there-
after on demand, according to patients’ needs. Hyalgan at
this regimen appears to be a safe and efﬁcacious treatment
for hip OA. The injection of a 4 ml volume in the hip joint is
well tolerated, and appeared to relieve pain and improve
function in our 12-month study.
The reduction in the number of injections made possible
by the administration of a double dose in a single solution
as compared with knee, where the dosage is ﬁve injections
performed once a week for 5 weeks, allows reducing the risk
connected with the procedure (i.e., infection, haematoma,
local painful reactions).
The concomitant reduction in NSAID intake observed in
our study due to the pain relief induced by Hyalgan is im-
portant as NSAID consumption carries a considerable bur-
den of side effects for the patient, especially gastrointestinal
and cardiologic, and raises disease-related costs. Function-
al improvement observed in our patients after Hyalgantreatment allows them to return to normal social and work-
ing activity, with further economic advantage. After the com-
pletion of the study, patients reported an overall better
quality of life when compared to the time of enrolment.
Further controlled and wider studies are warranted in or-
der to conﬁrm these results.
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